NEW ORLEANS – Patients with community-acquired pneumonia (CAP) who are undergoing therapy with antiplatelet medications experience a decreased risk of 30-day mortality, according to research presented at IDWeek 2016.
Paula Peyrani, MD, from the division of infectious diseases at the University of Louisville in Louisville, Kentucky, and colleagues conducted a secondary data analysis of the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study database to evaluate the adjusted impact that antiplatelet medications had on patients’ 30-day mortality risk.
The analysis included 3337 patients, 639 of whom received antiplatelet medication. Adjustments were made for confounding effects, at which point Dr Peyrani and colleagues determined that the risk ratio for patients taking antiplatelet medication was 0.55 (P <.001) compared with those not taking the medication.
The researchers observed that patients not taking antiplatelet medication had a shorter length of hospital stay probably because patients on the medication exhibited comorbidities such as higher rate of cardiac arrhythmia, renal disease, and congestive heart failure.
“This study indicates that hospitalized patients with CAP [who] were taking antiplatelet medications prior to hospitalization have a 45% decreased risk for mortality at 30 days,” Dr Peyrani and colleagues concluded. “Our data suggest that modifying inflammatory and coagulatory responses may be an important intervention to improve outcomes.”
Peyrani P, Wiemken T, Kelley R; and the CAPO Investigators. Do antiplatelet medications prevent poor clinical outcomes in patients with community-acquired pneumonia? Results from the CAPO International Cohort Study. Presentation at: ID Week 2016; October 26-30, 2016; New Orleans, LA. Abstract 906.